(-1.01%) 4 960.59 points
(0.31%) 37 891 points
(-2.18%) 15 261 points
(0.53%) $83.17
(-0.11%) $1.755
(0.50%) $2 410.10
(1.48%) $28.80
(-1.35%) $941.60
(-0.04%) $0.939
(-0.13%) $11.03
(0.55%) $0.808
(-0.93%) $93.02
Live Chart Being Loaded With Signals
Abliva AB (publ) develops medicines for the treatment of primary mitochondrial diseases. The company is developing KL1333 that is in Phase 2/3 clinical trials for the chronic treatment of primary mitochondrial diseases; NV354, which is in the preparation for clinical trials for the treatment of primary mitochondrial diseases with Complex I deficiency; and NeuroSTAT that is in Phase 1b/2a clinical study for traumatic brain injury...
Stats | |
---|---|
Today's Volume | 627 727 |
Average Volume | 1.43M |
Market Cap | 168.59M |
EPS | SEK0 ( 2024-02-22 ) |
Next earnings date | ( SEK0 ) 2024-05-23 |
Last Dividend | SEK0 ( N/A ) |
Next Dividend | SEK0 ( N/A ) |
P/E | -1.990 |
ATR14 | SEK0.00100 (0.63%) |
Volume Correlation
Abliva AB (publ) Correlation
10 Most Positive Correlations |
---|
10 Most Negative Correlations |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Abliva AB (publ) Correlation - Currency/Commodity
Abliva AB (publ) Financials
Annual | 2023 |
Revenue: | SEK137 000 |
Gross Profit: | SEK-97.89M (-71 454.74 %) |
EPS: | SEK-0.0904 |
Q4 | 2023 |
Revenue: | SEK137 000 |
Gross Profit: | SEK-24.67M (-18 005.84 %) |
EPS: | SEK-0.0239 |
Q3 | 2023 |
Revenue: | SEK0 |
Gross Profit: | SEK-8.52M (0.00 %) |
EPS: | SEK-0.0312 |
Q2 | 2023 |
Revenue: | SEK0 |
Gross Profit: | SEK-714 000 (0.00 %) |
EPS: | SEK-0.0202 |
Financial Reports:
No articles found.
Abliva AB (publ)
Abliva AB (publ) develops medicines for the treatment of primary mitochondrial diseases. The company is developing KL1333 that is in Phase 2/3 clinical trials for the chronic treatment of primary mitochondrial diseases; NV354, which is in the preparation for clinical trials for the treatment of primary mitochondrial diseases with Complex I deficiency; and NeuroSTAT that is in Phase 1b/2a clinical study for traumatic brain injury. It has collaboration agreements with Isomerase, Yungjin Pharm, University of Pennsylvania, Children's Hospital of Philadelphia, and Oroboros Instruments. The company was formerly known as NeuroVive Pharmaceutical AB (publ) and changed its name to Abliva AB (publ) in May 2020. Abliva AB (publ) was incorporated in 2000 and is headquartered in Lund, Sweden.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators